Skip to main content

Advertisement

Table 3 Impacts of gene mutations on relapse free and overall survival in 37 AML patients receiving IDAC and HiDAC consolidation

From: Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia

Factors Median RFS 1y-RFS 3y-RFS 5y-RFS Median OS 1y-OS 3y-OS 5y-OS
IDAC (Mo) p HiDAC (Mo) p IDAC (%) HiDAC (%) IDAC (%) HiDAC (%) IDAC (%) HiDAC (%) IDAC (Mo) p HiDAC (Mo) p IDAC (%) HiDAC (%) IDAC (%) HiDAC (%) IDAC (%) HiDAC (%)
Gene mutation
 FLT3-ITD 15 0.51 0.640 100 0 0 16 0.206 0.982 100 0 0
 NPM1 51 71 71 36 NR 100 83 83
 FLT3-ITD and NPM1 22 100 0 0 23 100 0 0
 CEBPA 13 12 100 50 NA NA NA NA 19 23 100 100 NA NA NA NA
 No mutation 11 11 50 50 29 38 0 38 22 31 86 90 27 36 NA 36
FLT3-ITD mutation
 Yes 15 0.813 100 0 0 16 0.192 100 0 0
 No 14 12 61 50 42 40 14 40 30 31 91 92 40 35 40 35
NPM1 mutation
 Yes 51 0.116 45 56 28 NR 0.116 100 69 69
 No 14 12 59 50 29 40 0 40 22 31 88 92 25 35 25 35
CEBPA mutation
 Yes 13 0.777 12 0.64 61 50 37 NA NA NA 19 0.797 23 0.982 100 100 NA NA NA NA
 No 14 11 50 50 NA 38 12 38 25 31 91 90 37 36 37 36
  1. NA not available